Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 11 to 20 of 2432 total matches.
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes ...
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular complications
in these trials with some sodium-glucose
co-transporter 2 (SGLT2) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists in patients at risk
for cardiovascular disease (see Table 1) have led to
new recommendations.
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only) ...
The FDA has warned that the investigational long-acting
monoclonal antibodies tixagevimab and
cilgavimab (Evusheld – AstraZeneca) are unlikely
to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2. Evusheld is available under an Emergency Use
Authorization (EUA) for IM pre-exposure prophylaxis of
COVID-19 in persons ≥12 years old who weigh ≥40 kg
and have either a history of a severe adverse reaction
that prevents their vaccination against COVID-19 or
moderate or severe immune compromise.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e25 doi:10.58347/tml.2023.1669e | Show Introduction Hide Introduction
Two New Doses of Dulaglutide (Trulicity) for Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
Two New Doses of Dulaglutide
(Trulicity) for Diabetes
Table 1. Results of AWARD-111
A1C Change ...
The FDA has approved two additional doses (3 mg
and 4.5 mg) of the glucagon-like peptide-1 (GLP-1)
receptor agonist dulaglutide (Trulicity – Lilly) for
treatment of type 2 diabetes in adults. Dulaglutide has
been available in 0.75- and 1.5-mg doses for years.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019 (Issue 1583)
-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA ...
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.
Oral Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2000 (Issue 1078)
known to decrease acne.
SOME ORAL CONTRACEPTIVES
Drug Estrogen (µg)
1
Progestin (mg)
2
Cost
3 ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Comparison Chart: SGLT2 Inhibitors (online only)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
2 (SGLT2) INHIBITORS RENAL DOSAGE ADJUSTMENTS CANAGLIFLOZIN eGFR 30 to ...
View the Comparison Chart: SGLT2 Inhibitors
Yasmin -- an Oral Contraceptive With a New Progestin
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002 (Issue 1133)
-years of use,
which is similar to rates with other combination OCs. A 1-year study found 1 pregnancy ...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
and Moderna
vaccines are no longer authorized for use in the US.1-3
THE NEW VACCINES – The new formulations ...
New 2023-2024 formulations of the mRNA COVID-19
vaccines manufactured by Pfizer/BioNTech
(Comirnaty) and that more
closely target currently circulating variants have
been licensed by the FDA for use in persons ≥12 years
old and made available under FDA Emergency Use
Authorizations (EUAs) for use in persons 6 months
to 11 years old. The bivalent (original and Omicron
BA.4/5) formulations of the Pfizer and Moderna
vaccines are no longer authorized for use in the US.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):167-8 doi:10.58347/tml.2023.1687c | Show Introduction Hide Introduction
In Brief: Calcium and Vitamin D to Prevent Osteoporotic Fractures
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
/day) will benefit from
taking supplements.1
Table 1. Calcium Content of Some Foods1
Serving Calcium ...
The US Preventive Services Task Force (USPSTF) has issued a Draft Recommendation Statement saying, in effect, that community-dwelling women and men should not take calcium and vitamin D supplements for primary prevention of osteoporotic fractures because the evidence that they are helpful is insufficient and they increase the risk of kidney stones. The Medical Letter has said previously that there is no evidence that patients with an adequate intake of calcium (1000-1200 mg/day) and vitamin D (600-800 IU/day) will benefit from taking supplements.11. Drugs for postmenopausal osteoporosis. Treat...
COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
oxygenation (ECMO).1
Baricitinib was previously available for this indication
under an Emergency Use ...
The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for use in children 2-17 years old hospitalized with COVID-19 who require oxygen support.